Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
| ▸ | CFTR | P13569 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | YEATS4 | O95619 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18152630 | 0.76 | ALDH1A1 (0.38) | SMN1; SMN2KDM4EUSP2ALDH1A1CYP1A2 | |
| SCHEMBL29200211 | 0.73 | KDM4E (0.35) | SMN1; SMN2KDM4EUSP2ALDH1A1CYP1A2 | |
| SCHEMBL22017086 | 0.73 | ALOX5 (0.38) | SMN1; SMN2KDM4EUSP2ALDH1A1CYP1A2 | |
| SCHEMBL15742528 | 0.72 | ALDH1A1 (0.34) | SMN1; SMN2KDM4EUSP2ALDH1A1CYP1A2 | |
| SCHEMBL22016184 | 0.71 | TLR8 (0.32) | SMN1; SMN2KDM4EUSP2ALDH1A1CYP1A2 | |
| SCHEMBL9665568 | 0.71 | ALDH1A1 (0.35) | SMN1; SMN2KDM4EUSP2ALDH1A1CYP1A2 | |
| SCHEMBL29161593 | 0.70 | ALDH1A1 (0.38) | SMN1; SMN2KDM4EUSP2ALDH1A1HSD17B10 | |
| SCHEMBL12857421 | 0.70 | HPGD (0.34) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL29161623 | 0.69 | ALDH1A1 (0.40) | SMN1; SMN2KDM4EUSP2ALDH1A1HSD17B10 | |
| SCHEMBL23900704 | 0.68 | KDM4E (0.36) | KDM4EUSP2ALDH1A1CYP1A2BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230041518-A1 | QUINOLINE DERIVATIVES | GILEAD SCIENCES, INC. | 2023-02-09 | — | — | US | disclosed |
| US-20220119383-A1 | QUINOLINE DERIVATIVES AS ALPHA4BETA7 INTEGRIN INHIBITORS | GILEAD SCIENCES, INC. | 2022-04-21 | — | — | US | disclosed |
| US-11174256-B2 | Imidazopyridine derivatives | GILEAD SCIENCES, INC. (US) | 2021-11-16 | — | — | US | disclosed |
| US-11116760-B2 | Quinoline derivatives | GILEAD SCIENCES, INC. (US) | 2021-09-14 | — | — | US | disclosed |
| US-20200155538-A1 | QUINOLINE DERIVATIVES | GILEAD SCIENCES, INC. | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230041518-A1 | QUINOLINE DERIVATIVES | CFTR, NQO1, IRF3 | SMN1; SMN2 1294/4885KDM4E 2522/4885USP2 2720/4885 |
| US-20200155538-A1 | QUINOLINE DERIVATIVES | CFTR, NQO1, IRF3 | SMN1; SMN2 1294/4885KDM4E 2522/4885USP2 2720/4885 |
| US-20220119383-A1 | QUINOLINE DERIVATIVES AS ALPHA4BETA7 INTEGRIN INHIBITORS | ITGB7, ITGB1, ITGA2B | SMN1; SMN2 3146/4885KDM4E 1390/4885USP2 4264/4885 |
| US-11174256-B2 | Imidazopyridine derivatives | TPMT, IRAK4, CFTR | SMN1; SMN2 423/4885KDM4E 2655/4885USP2 4232/4885 |
| US-11116760-B2 | Quinoline derivatives | CFTR, NQO1, IRF3 | SMN1; SMN2 1294/4885KDM4E 2522/4885USP2 2720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.